Advanced Therapies - Optimize Product Recovery and Scalability
Advanced therapies benefit from systems that minimize contamination risks to the product as well as to the environment, enable high product recovery and fast processing times. The UniFuge® cell processing platform effectively addresses these needs.
The UniFuge single-use centrifuges use tubular bowl technology to enable fast cell processing speeds, minimize shear forces, and maintain separation efficiency.
Advanced Therapies Case Studies and Resources
Navigating the Challenges of iPSC Differentiation: The Advantages of Tubular Bowl Centrifuges in Media Exchange
Tubular bowl centrifugation, a technology traditionally used for the final harvest of cell therapies, has been utilized to provide the gentle and rapid exchange of media in bioreactors during expansion and differentiation of iPSCs. The tubular bowl centrifuge stands out for its gentle handling of cells, rapid processing times and scalability, making it an ideal solution for media exchange during the culture of iPSCs in both research and clinical settings.
UniFuge Cell Processing Platform Video
The UniFuge cell processing platform offers unparalleled scale-down capabilities using tubular-bowl technology to separate cells gently and effectively. This paper demonstrates how single-use centrifuges perform through scale-up activities in aspects such as turbidity reduction, shear forces on cells, and minimization of downstream impurities. Additionally, centrifugation as a primary separation approach offers benefits including reduced contamination risks, building space, and buffer requirements due to a reduction in depth filtration.
Scaling Primary Clarification with Tubular Bowl Centrifugation
The UniFuge cell processing platform's robust process parameter range and scalability enable developers to tune manufacturing strategies based on cell culture characteristics, process goals and manufacturing objectives. The inherent separation efficiency of tubular bowl centrifuges and low shear environment enables developers to reduce primary and secondary filtration requirements while balancing processing speed.
Contact Us for Advanced Therapies Resources and Product Information
Additional Resource Topics
Performance
Our proven low-shear technology boasts up to 98% yield and 98% or higher typical cell viability.
Scalability
Our equipment can be used from development to commercial licensure and across different reactor volumes.
Ease of Use
Our machines are rapid to install and simple to operate.
Small Footprint
Our single-use centrifuges have a small footprint.